O007. - COMPREHENSIVE ASSESSMENT OF SARCOPENIA IN PATIENTS WITH SEVERE AORTIC STENOSIS UNDERGOING TRANSCATHETER VALVE IMPLANTATION

O007.

COMPREHENSIVE ASSESSMENT OF SARCOPENIA IN PATIENTS WITH SEVERE AORTIC STENOSIS UNDERGOING TRANSCATHETER VALVE IMPLANTATION

A. Stapor^1,*, M. Stapor², E. Ostrowska-Kaim³, A. Misiuda³, J. Trebacz⁴, P. Kleczynski², K. Zmudka², J. Legutko²

¹Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, ²Institute of Cardiology, Department of Interventional Cardiology, Jagiellonian University Medical College, Faculty of Medicine, ³ St. John Paul II Hospital, Noninvasive Cardiovascular Laboratory, ⁴St. John Paul II Hospital, Clinical Department of Interventional Cardiology, Cracow, Poland

Rationale: Transcatheter aortic valve implantation (TAVI) has become a highly effective treatment for aortic stenosis (AS), particularly in aging, frail, and sarcopenic populations. This study aimed to comprehensively analyze the prevalence of sarcopenia in patients undergoing TAVI and evaluate its imaging and functional markers.

Methods: This prospective single-center study included consecutive patients aged ≥75 years scheduled for elective TAVI for symptomatic severe AS. Sarcopenia was assessed per the 2018 European Working Group on Sarcopenia in Older People 2 criteria, including muscle strength (hand grip, chair stand), muscle quantity (computed tomography, bioelectrical impedance, ultrasound), and physical performance (Short Physical Performance Battery, Timed Up and Go, 5-Meter and 6-Minute Walk). 

Results: Thirty patients (83.2 years, SD 16) with severe aortic stenosis (AVA 0.79 cm², SD 0.15), preserved left ventricular systolic function (EF 60, IQR 50-62), and moderate procedural risk (STS score 3.91%, IQR 2.2-7.76) were included. Probable sarcopenia was identified in 83.33% (25) of patients. All subjects had low physical performance, and 86.67% (26) exhibited low muscle quantity. These findings led to a direct diagnosis of severe sarcopenia in 73.33% (20) of patients. Very strong statistically significant correlations were observed between fat-free mass assessed by bioelectrical impedance and total psoas muscle cross-sectional area at the L4 level (R = 0.791, P < 0.001), as well as total muscle cross-sectional area at the L3 level (R = 0.722, P < 0.001).

Conclusion: Sarcopenia is highly prevalent among patients undergoing TAVI. Bioimpedance-derived body composition parameters show a statistically significant correlation with computed tomography measurements.

Disclosure of Interest: None declared